2026-08455NoticeWallet

FDA Yanks Drug Approval: Lies and Lies in Medicine's Pipeline?

Published Date: 4/30/2026

Notice

Summary

The FDA wants to take back its approval of the drug TAVNEOS, made by ChemoCentryx, because new info shows it might not work as promised and some facts in the application weren’t true. ChemoCentryx can ask for a hearing by June 1, 2026, to defend their drug. This could affect patients using TAVNEOS and might shake up the company’s plans and finances.

Analyzed Economic Effects

3 provisions identified: 1 benefits, 1 costs, 1 mixed.

FDA Proposes Withdrawal of TAVNEOS Approval

The FDA is proposing to withdraw approval of TAVNEOS (avacopan) capsule, 10 mg, which the agency originally approved on October 7, 2021 for adjunctive treatment of adult patients with severe active ANCA-associated vasculitis. The agency's grounds are that new information shows manipulated study data and untrue statements of material fact, so there is a lack of substantial evidence that the drug is effective under the labeled conditions.

Postmarket Safety Signals: Liver Risks

FDA identified hepatotoxicity as a key safety risk for avacopan and noted serious and sometimes fatal hepatotoxicity cases reported after approval. Recent postmarketing safety reports also suggest avacopan may be associated with vanishing bile duct syndrome (VBDS), an unexpected serious adverse event.

Hearing and Comment Deadlines Set

ChemoCentryx (the applicant) may request a hearing on the proposed withdrawal by June 1, 2026, and must submit all data and analyses supporting a hearing request by June 29, 2026. Other interested parties may submit electronic or written comments by June 29, 2026.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Comments Due
4/30/2026
6/29/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register